End-of-day quote
Other stock markets
|
||
- CHF | - |
|
06-24 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
06-24 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
Sales 2024 * | 49.13B 44.13B 67.19B | Sales 2025 * | 51.26B 46.05B 70.11B | Capitalization | 218B 196B 299B |
---|---|---|---|---|---|
Net income 2024 * | 10.45B 9.39B 14.29B | Net income 2025 * | 11.7B 10.51B 16B | EV / Sales 2024 * | 4.7 x |
Net Debt 2024 * | 12.71B 11.42B 17.39B | Net Debt 2025 * | 10.76B 9.67B 14.72B | EV / Sales 2025 * | 4.47 x |
P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
18.1
x | Employees | - |
Yield 2024 * |
3.41% | Yield 2025 * |
3.54% | Free-Float | 85.22% |
Latest transcript on Novartis AG
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+8.48% | 168B | |
-2.81% | 159B | |
+0.20% | 120B |